CALIBRATE: Interim Week 28 Results of Long-acting Subcutaneous Lenacapavir in Treatment-Naive Patients

July 18-21, 2021; Virtual
After 2-week oral lead-in, treatment with oral or subcutaneous lenacapavir plus FTC/TAF associated with high rates of virologic suppression.
Format: Microsoft PowerPoint (.ppt)
File Size: 227 KB
Released: July 24, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Commentary on lessons learned during the COVID-19 pandemic for reducing barriers to HIV prevention service access, from Clinical Care Options (CCO)

Latesha Elopre, MD, MSPH Michael A. Fordham, BA Released: December 7, 2021

Dr Karen Ha and Clinical Care Options (CCO): Data suggests there is a role for NNRTIs in current practice, including for patients who have experienced weight gain with INSTI-based ART.

Karen Ha, MD Released: December 6, 2021

Dr Milosz Parczewski and Clinical Care Options (CCO): Update from EACS 2021 on the HIV care continuum in Eastern Europe

Milosz Parczewski, MD, PhD Released: December 3, 2021

Expert recap of new data on rapid ART with BIC/FTC/TAF from EACS 2021, from Dr Monica Gandhi at Ward 86 and Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue